logo
8 babies born with DNA from 3 people in world-first IVF trial aimed at minimizing risk of inherited disease

8 babies born with DNA from 3 people in world-first IVF trial aimed at minimizing risk of inherited disease

CBS News4 days ago
Eight healthy babies have been born in the U.K. using a new IVF technique that successfully reduced their risk of inheriting genetic diseases from their mothers, the people behind a world-first trial said Wednesday.
The findings were hailed as a breakthrough, which raises hopes that women with mutations in their mitochondrial DNA could one day have children without passing debilitating or deadly diseases on to the children. One out of every 5,000 births is affected by mitochondrial diseases, which cannot be treated, and include symptoms such as impaired vision, diabetes and muscle wasting.
In 2015, Britain became the first country to approve an in-vitro fertilization technique that uses a small amount of healthy mitochondrial DNA from the egg of a donor — along with the mother's egg and father's sperm.
Some have called the result of this process "three-parent babies," though researchers have pushed back at this term because only roughly 0.1% of the newborn's DNA comes from the donor.
The results of the much-awaited U.K. trial were published in several papers in the New England Journal of Medicine.
Out of 22 women to undergo the treatment at the Newcastle Fertility Centre in northeast England, eight babies were born. The four boys and four girls now range from under 6 months to over 2 years old.
The amount of mutated mitochondrial DNA — which causes disease — was reduced by 95-100% in six of the babies, according to the research. For the other two newborns, the amount fell by 77-88%, which is still below the range that causes disease.
This indicates the technique was "effective in reducing transmission" of diseases between mother and child, one of the studies said.
The eight children are currently healthy, though one had a disturbance of their heart's rhythm which was successfully treated, the researchers said.
Their health will be followed up over the coming years to see if problems arise.
Oxford University reproductive genetics expert Dagan Wells noted that among the eight children, three have shown some signs of what is known as "reversal," which is still little understood.
It is "a phenomenon where the therapy initially succeeds in producing an embryo with very few defective mitochondria, but by the time the child is born the proportion of abnormal mitochondria in its cells has significantly increased," he explained.
Nevertheless, Nils-Goran Larsson, a Swedish reproductive expert not involved in the research, hailed it as a "breakthrough."
The new technique offers a "very important reproductive option" for families affected by "devastating" mitochondrial diseases, he added.
While the U.K. trial is the first to involve multiple mothers, the eight babies born to them are not the first to be born with DNA from three people. That first came in 2016, after a woman was treated by U.S. fertility specialists in Mexico, where there were no laws regulating the practice. A similar IVF method was used in that groundbreaking case.
Mitochondrial donation remains controversial and has not been approved in many countries, including the United States and France.
Religious leaders have opposed the procedure because it involves the destruction of human embryos. Other opponents have expressed fears it could pave the way for genetically engineered "designer babies."
An ethical review carried out by the U.K.'s independent Nuffield Council on Bioethics was "instrumental" in conducting the new research, the council's director Danielle Hamm said Wednesday.
Peter Thompson, head of the U.K.'s Human Fertilisation and Embryology Authority, which approved the procedure, said only people with a "very high risk" of passing on a mitochondrial disease would be eligible for the treatment.
Ethical concerns have also been raised over the use of mitochondrial donation for infertility in Greece and Ukraine.
French mitochondrial disease specialist Julie Steffann told AFP that "it is a question of the risk-benefit ratio: for a mitochondrial disease, the benefit is obvious."
"In the context of infertility, it has not been proven," she added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

I took the DWP to court and won - but it was the worst time of my life
I took the DWP to court and won - but it was the worst time of my life

Yahoo

time29 minutes ago

  • Yahoo

I took the DWP to court and won - but it was the worst time of my life

A man fighting to claim PIP at a court tribunal said it was "the worst two hours of my life" as he spoke about his struggles claiming benefits while dealing with Parkinson's. Steve Johnson, a self-employed farmer based near Thirsk, North Yorkshire, took the DWP to court to fight for his entitlement to disability benefit PIP after he was diagnosed with the progressive neurological condition in 2020. Johnson, who also cares for his wife Gilly, who lives with MS, currently receives universal credit and the daily living component of personal independence payment (PIP). When he first applied for PIP, he was awarded zero points. He felt the assessment assumed that because he worked in agriculture, he must be physically fit. However, he was struggling with his symptoms of Parkinson's, such a his right-sided tremor, difficulties sleeping, and loss of strength. Charities like Parkinson's UK have raised significant concerns about how recent and proposed government benefit cuts could disproportionately affect people with conditions like Parkinson's because symptoms can present differently from one day to the next. Current benefit assessments are often under scrutiny for failing to understand or account for fluctuating conditions like Parkinson's, leading to people like Steve being refused PIP payments by the DWP. While PIP payments avoided the chopping block in the latest round of government cuts, the disability benefit is up for investigation next Autumn, when the government will explore the impact of restricting the eligibility criteria for the payment. Success rates for taking the DWP to tribunal for PIP appeals are consistently high, with around 60-70% of cases assessed at court overturning the DWP's decision, Johnson said the stress of the process significantly worsened his symptoms. He told Yahoo News: 'My stress levels went through the roof. It just made my symptoms 10 times worse.' 'They twisted everything I said' Speaking about applying for PIP, Johnson told Yahoo News: "I applied for PIP with some assistance. I had a telephone assessment and I got one of the most upsetting letters back I've ever read. "They twisted everything I said. There's several times in this refusal letter that said, because I cared for my wife, I must be all right. Because I worked in agriculture, I must be all right. "My GP was incensed. He read the letter and said, do they have any idea what Parkinson's is? He then wrote to them to back me up. "My mandatory reconsideration came back, even with extra evidence, And it was just a cut and paste. It was just a generic, computer says no response. It didn't even mention Parkinson's. Left without an option, Johnson decided to take his PIP case to tribunal. While the farmer was advised that he had a very strong case, he didn't realise how nerve-racking it would be. He said: "It was so hard. I remember trying to drink a glass of water because my throat was dry, and then my tremor went into overdrive. At one point, his home was pulled up on Google Maps by the court while he was questioned about walking to the local shop. "They said, according to Google Maps, your local village shop its 750 metres away. Could you get to the village shop? Could you walk?," he explained. "I said, I don't know, I've not walked to the village shop two or three years now. "They made me give an answer on a guess. All of a sudden, a guess was taken as a definitive answer. "I was just mentally, physically, emotionally, absolutely drained," he added. A few days later, Johnson found out his appeal was successful. "We didn't get the decision there and then we got a letter a few days later and sure enough, they've given me the full 12 points for daily living, and four for mobility," he said. While Johnson was overjoyed to finally have the support, the experience took its toll. "It was two hours of the worst time of my life," he added. 'It's like a hidden trap door' Sadly, the farmer's benefits battle is far from over. Now, he is fighting to challenge the DWP after his transitional protection was removed from his universal credit payments when his income dipped. When a person is taken off a legacy benefit — like working tax credits, in Steve's case — and moved onto universal credit, they have a 12-month guarantee that they will not be worse off when they move to the new system. But as Johnson explains, self-employed farmers experience "feast or famine", so his income can vary significantly from month to month. Earlier this year, the farmer was alarmed to discover his universal credit benefits support dried up, and in his worst month, he received zero support. He told Yahoo News: "We went through three months of where I wasn't doing enough work, I wasn't selling cattle, but I had to pay the contractors. So I had a lot of bills and so I had a negative bank balance. "But it triggered this lower threshold rule, where the DWP apparently says if your income dips below a certain level — which they don't tell you about this until it happens — the government takes off your transitional protection. "We went from getting £986 to £800, then zero the next month." Steve is hoping to take part in a mass appeal investigating the impact of lower income threshold issues affecting transitional protection. "To me, it is fraud. How come the DWP are not carrying on my profits but my losses are included in my totals? "It's like a hidden trap door they don't really talk about. Then when I started challenging it, I was told it's in my claimant commitment. "It isn't in my commitment at all, it's only written in the law itself. It's hidden." 'We'll keep fighting' While Johnson receives the universal credit health top-up, people with Parkinson's hoping for support after April 2026 are likely to see their support halved under the government's welfare bill, Parkinson's UK has warned. While the government said 200,000 people with severe conditions will still be entitled to the higher rate of universal credit health top up once the payments are cut £97 p/w in April 2026 to £50 p/w, there are fears Parkinson's patients will not qualify as severe because of a lack of understanding about how Parkinson's affects day to day life. As the chart below illustrates, those with neurological conditions will be among the hardest hit should the PIP cuts go ahead next year, with around 38% of claimants projected to be affected. "The government's decision to cut universal credit costs is appalling. We believe that, despite the government's claims, savings are being made by effectively making people with Parkinson's ineligible for the higher rate health element," Juliet Tizzard, the director of external relations at Parkinson's UK, told Yahoo News. "The bill clearly states that someone must be constantly unable to do certain tasks to qualify. This will penalise people with Parkinson's, whose symptoms come and go. Until we can be certain that people with fluctuating conditions will not be penalised, we'll continue campaigning for a fair system. "We're thankful to the MPs who tried to stop the changes to universal credit, and for every campaigner who raised their voice. "We stopped the cuts to PIP, and while we're disappointed by the result today, this setback won't stop us. We'll keep fighting for better support, care and treatment for the Parkinson's community." The government has been approached for comment.

TNT Shows Similar Efficacy Across Regimens in Rectal Cancer
TNT Shows Similar Efficacy Across Regimens in Rectal Cancer

Medscape

time30 minutes ago

  • Medscape

TNT Shows Similar Efficacy Across Regimens in Rectal Cancer

TOPLINE: In a multicentre study of patients with locally advanced rectal cancer, substantial variation existed in the choice of total neoadjuvant therapy (TNT), but efficacy was comparable across different regimens and consistent with that reported in clinical trials. METHODOLOGY: Researchers conducted an international, multicentre study in 21 countries and included 1585 patients (median age, 61 years; 37.1% women) with stage II/III rectal adenocarcinoma from September 2012 to December 2023. The primary objective focused on the type of TNT administered depending on the regimen, timing and type of chemotherapy, and type of radiotherapy. Secondary objectives encompassed safety and efficacy overall and on the basis of the type of TNT after propensity vector matching. Efficacy endpoints included pathologic complete response, complete response, local or distant progression at the time of treatment failure, event-free survival (EFS), and overall survival (OS). Overall, 17.7%, 33.4%, 12%, and 16.2% of patients were treated according to PRODIGE 23-like, RAPIDO-like, OPRA induction-like, and OPRA consolidation-like regimens, respectively. TAKEAWAY: Chemotherapy was given as induction, consolidation, and sandwich for 34.5%, 51.0%, and 14.5% of patients, respectively; regimens were single agent (1.1%), doublet (78.8%), and triplet (20.1%). Radiotherapy was delivered as short-course radiotherapy in 37.2% and long-course chemoradiotherapy in 62.8% of cases. The pathologic complete response rate was 21.3%, and the complete response rate was 23.2%; local and distant progression at the time of treatment failure were 7% and 16.2%, respectively. Three-year EFS reached 68%, and 5-year OS was 79%. In the overall population, PRODIGE 23-like regimens showed better survival outcomes than RAPIDO-like regimens (EFS: hazard ratio [HR], 0.68; P = .03; OS: HR, 0.51; P = .04), OPRA induction-like regimens (EFS: HR, 0.66; P = .04; OS: HR, 0.35; P = .003), and OPRA consolidation-like regimens (EFS: HR, 0.64; P = .02; OS: HR, 0.50; P = .05). After the propensity vector matching analysis of 928 patients (58.5%), no significant differences in survival outcomes were observed between TNT regimens. IN PRACTICE: "This case series study illuminates the applicability of TNT to clinical practice," the authors of the study wrote. "TNT decisions should be made based on the individual risk profile and following an accurate discussion about the positives and negatives of each option while considering patient preferences and expectations," they added. SOURCE: This study was led by Alessandro Audisio, MD, Université libre de Bruxelles, Institut Jules Bordet-Hôpital Erasme, Brussels, Belgium. It was published online on July 10, 2025, in JAMA Oncology. LIMITATIONS: The retrospective design of the study introduced potential data collection errors and biases, which were only partially addressed through remote monitoring and data imputation. The relatively short follow-up period may have prevented the detection of differences in long-term outcomes between TNT regimens. Additionally, variations in treatment delivery, staging methods, and supportive care across institutions complicated direct comparisons. Despite involving multiple countries, the predominant European patient population limited the generalisability of the results. DISCLOSURES: This study was sponsored by the Institut Jules Bordet and endorsed by the Oncodistinct Network. Several authors reported receiving personal fees and grants and having other ties with various sources. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Extensively Drug-Resistant TB Outcomes Remain Poor in Europe
Extensively Drug-Resistant TB Outcomes Remain Poor in Europe

Medscape

time30 minutes ago

  • Medscape

Extensively Drug-Resistant TB Outcomes Remain Poor in Europe

TOPLINE: Only four out of 10 patients with extensively drug-resistant tuberculosis in Europe achieved successful treatment outcomes, a rate markedly lower than that for other forms of drug-resistant tuberculosis and comparable with cure rates from the pre-antibiotic era. METHODOLOGY: Researchers conducted a retrospective observational cohort study across 16 countries of the World Health Organization (WHO) European Region to evaluate treatment outcomes in 188 patients (median age, 42 years; 79.3% men) with extensively drug-resistant tuberculosis. Data collected included patient characteristics, disease localisation, prior treatments, phenotypic and genotypic drug susceptibility testing results, and treatment regimens. Treatment outcomes were categorised as successful, failure (microbiological or clinical reasons including regimen changes), lost to follow-up (treatment interrupted for 2 or more months), or not evaluated. TAKEAWAY: Among the 188 patients with extensively drug-resistant tuberculosis, 48.4%, 34.0%, and 17.6% of Mycobacterium tuberculosis strains were resistant to bedaquiline alone, linezolid alone, and both drugs, respectively. Among 156 patients with available data for treatment outcomes, 40.2% (95% CI, 28.4%-53.2%) achieved successful outcomes in a pooled analysis accounting for between-country heterogeneity. Patients with extensively drug-resistant tuberculosis had lower pooled success rates (P < .0001) and significantly higher pooled rates of treatment failure and death (P < .0001 and P = .008, respectively) than those with multidrug-/rifampicin-resistant or preextensively drug-resistant tuberculosis. The likelihood of an unsuccessful outcome decreased with each additional effective drug in the regimen (P = .026) but increased among patients treated in upper-middle-income countries compared with that among those treated in high-income countries (P < .001). IN PRACTICE: "[The study] findings underscore the need for improved, rapid DST [drug susceptibility testing] tools and effective, shorter treatment regimens for extensively drug-resistant tuberculosis," the authors wrote. SOURCE: This study was led by Yousra Kherabi, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, and Ole Skouvig Pedersen, Aarhus University Hospital, Aarhus, Denmark. It was published online on July 15, 2025, in The Lancet Regional Health - Europe. LIMITATIONS: The coverage of the WHO European Region was limited. Most of the participating centres were specialist or referral centres, which may have introduced selection bias and limiting generalisability. Although the use of WHO-defined outcomes simplified data collection, it constrained a detailed understanding of treatment failures. Moreover, individual-level data were available only for patients with extensively drug-resistant tuberculosis, which may have introduced confounding from unmeasured patient-level factors. DISCLOSURES: This study did not receive any funding. One author reported serving as a co-principal investigator of clinical trials testing new regimens for multidrug-resistant tuberculosis, and some authors reported receiving honoraria for speaking engagements or serving on advisory boards of various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store